{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:18:51Z","timestamp":1791202731621,"version":"4.2.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,4,18]],"date-time":"2007-04-18T00:00:00Z","timestamp":1176854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00280-007-0486-8","type":"journal-article","created":{"date-parts":[[2007,4,18]],"date-time":"2007-04-18T13:43:46Z","timestamp":1176903826000},"page":"435-441","source":"Crossref","is-referenced-by-count":63,"title":["A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma"],"prefix":"10.1007","volume":"61","author":[{"given":"Robert J.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Eatock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry A. L. M.","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HansJochen","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. R. Jeffry","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,4,18]]},"reference":[{"key":"486_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/bjs.1800760604","volume":"76","author":"WH Allum","year":"1989","unstructured":"Allum WH, Powell DJ, McConkey CC, Fielding JW (1989) Gastric cancer\u2014a 25-year review. Br J Surg 76:535\u2013540","journal-title":"Br J Surg"},{"key":"486_CR2","doi-asserted-by":"crossref","unstructured":"Medical Research Council Oesophageal Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 359:1727\u20131733","DOI":"10.1016\/S0140-6736(02)08651-8"},{"key":"486_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A, et al (1993) Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72:37\u201341","journal-title":"Cancer"},{"key":"486_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a058778","volume":"5","author":"B Glimelius","year":"1994","unstructured":"Glimelius B, Hoffman K, Haglund U, et al (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189\u2013190","journal-title":"Ann Oncol"},{"key":"486_CR5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrhonen","year":"1995","unstructured":"Pyrhonen S, Kuitonen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587\u2013591","journal-title":"Br J Cancer"},{"key":"486_CR6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a058932","volume":"5","author":"M Findlay","year":"1994","unstructured":"Findlay M, Cunningham D, Norman A, et al (1994) A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609\u2013616","journal-title":"Ann Oncol"},{"key":"486_CR7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0959-8049(97)86090-X","volume":"15","author":"A Webb","year":"1997","unstructured":"Webb A, Cunningham D, Scarffe JH, et al (1997) Randomised trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261\u2013267","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"486_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdf633","volume":"13","author":"P Schoffski","year":"2002","unstructured":"Schoffski P (2002) New drugs for treatment of gastric cancer. Ann Oncol 13(Suppl 4):13\u201322","journal-title":"Ann Oncol"},{"key":"486_CR9","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/sj.bjc.6601364","volume":"89","author":"MB Polee","year":"2003","unstructured":"Polee MB, Hop WC, Kok TC (2003) Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 89:2045\u20132050","journal-title":"Br J Cancer"},{"key":"486_CR10","first-page":"4090","volume":"42","author":"LA Sauer","year":"1982","unstructured":"Sauer LA, Stayman JW III, Dauchy RT (1982) Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res 42:4090\u20134097","journal-title":"Cancer Res"},{"key":"486_CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1042\/bst0180080","volume":"18","author":"LA Sauer","year":"1990","unstructured":"Sauer LA, Dauchy RT (1990) Tumour-host metabolic inter-relationships. Biochem Soc Trans 18:80\u201382","journal-title":"Biochem Soc Trans"},{"key":"486_CR12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/bjc.1992.259","volume":"66","author":"LA Sauer","year":"1992","unstructured":"Sauer LA, Dauchy RT (1992) Uptake of plasma lipids by tissue-isolated hepatomas 7288CTC and 7777 in vivo. Br J Cancer 66:290\u2013296","journal-title":"Br J Cancer"},{"key":"486_CR13","first-page":"3229","volume":"7","author":"MO Bradley","year":"2001","unstructured":"Bradley MO, Webb NL, Anthony FH, et al (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7:3229\u20133238","journal-title":"Clin Cancer Res"},{"key":"486_CR14","first-page":"3589","volume":"9","author":"AC Wolff","year":"2003","unstructured":"Wolff AC, Donehower RC, Carducci MK, et al (2003) Phase I study of docosahexaenoic acid-paclitaxel: a fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589\u20133597","journal-title":"Clin Cancer Res"},{"key":"486_CR15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"486_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P, et al (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"486_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"486_CR18","first-page":"269","volume":"4","author":"JA Ajani","year":"1998","unstructured":"Ajani JA, Fairweather J, Dumas P, et al (1998) Phase II trial of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4:269\u2013274","journal-title":"Cancer J Sci Am"},{"issue":"5 Suppl 8","key":"486_CR19","first-page":"40","volume":"21","author":"D Kelsen","year":"1994","unstructured":"Kelsen D, Ajani J, Ilson D, et al (1994) A phase II trial of paclitaxel (taxol) in advanced esophageal cancer: preliminary report. Sem Oncol 21(5 Suppl 8):40\u201348","journal-title":"Sem Oncol"},{"key":"486_CR20","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","volume":"86","author":"JA Ajani","year":"1994","unstructured":"Ajani JA, Ilson DH, Daugherty K, et al (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086\u20131091","journal-title":"J Natl Cancer Inst"},{"key":"486_CR21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00000421-200008000-00005","volume":"23","author":"D Mavroudis","year":"2000","unstructured":"Mavroudis D, Kourousis C, Androulakis N, et al (2000) Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 23:341\u2013344","journal-title":"Am J Clin Oncol"},{"issue":"Suppl 6","key":"486_CR22","first-page":"35","volume":"22","author":"JA Ajani","year":"1995","unstructured":"Ajani JA, Ilson DH, Daugherty K, Kelsen DP (1995) Paclitaxel in the treatment of cancer of the oesophagus. Sem Oncol 22(Suppl 6):35\u201340","journal-title":"Sem Oncol"},{"key":"486_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02993858","volume":"13","author":"AI Einzig","year":"1996","unstructured":"Einzig AI, Neuberg D, Remick SC, et al (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13:87\u201393","journal-title":"Med Oncol"},{"key":"486_CR24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bjc.1994.310","volume":"70","author":"A Sulkes","year":"1994","unstructured":"Sulkes A, Smyth J, Sessa C, et al (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70:380\u2013383","journal-title":"Br J Cancer"},{"key":"486_CR25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00000421-199808000-00021","volume":"21","author":"A Ohtsu","year":"1998","unstructured":"Ohtsu A, Boku N, Tamura F, et al (1998) An early phase II study of a 3-h infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416\u2013419","journal-title":"Am J Clin Oncol"},{"key":"486_CR26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00001813-199804000-00003","volume":"9","author":"S Cascinu","year":"1998","unstructured":"Cascinu S, Graziano F, Cardarelli N, et al (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anti-Cancer Drugs 9:301\u2013310","journal-title":"Anti-Cancer Drugs"},{"issue":"16S","key":"486_CR27","first-page":"3085","volume":"23","author":"VM Moiseyenko","year":"2005","unstructured":"Moiseyenko VM, Ajani J, Tjulandin SA, et al (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGCI). J Clin Oncol 23(16S):3085","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0486-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0486-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0486-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:46Z","timestamp":1559038006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0486-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,18]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0486-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,18]]}}}